Approved for Treatment of bronchospasm associated with COPD including chronic bronchitis and emphysema. Ipratropium is an anticholinergic (parasympatholytic) agent that blocks muscarinic receptors in bronchial smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction and reducing mucus… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels,…
Loading full data from Know Your Drugs Institute…